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Abstract
Introduction Tamoxifen therapy reduces the risk of recurrence
and prolongs the survival of oestrogen-receptor-positive
patients with breast cancer. Even if most patients benefit from
tamoxifen, many breast tumours either fail to respond or become
resistant. Because tamoxifen is extensively metabolised by
polymorphic enzymes, one proposed mechanism underlying the
resistance is altered metabolism. In the present study we
investigated the prognostic and/or predictive value of functional
polymorphisms in cytochrome P450 3A5 CYP3A5 (*3),
CYP2D6 (*4), sulphotransferase 1A1 (SULT1A1; *2) and UDP-
glucuronosyltransferase 2B15 (UGT2B15; *2) in tamoxifen-
treated patients with breast cancer.
Methods In all, 677 tamoxifen-treated postmenopausal patients
with breast cancer, of whom 238 were randomised to either 2
or 5 years of tamoxifen, were genotyped by using PCR with
restriction fragment length polymorphism or PCR with
denaturing high-performance liquid chromatography.
Results The prognostic evaluation performed in the total
population revealed a significantly better disease-free survival in
patients homozygous for CYP2D6*4. For CYP3A5, SULT1A1
and UGT2B15 no prognostic significance was observed. In the
randomised group we found that for CYP3A5, homozygous
carriers of the *3  allele tended to have an increased risk of
recurrence when treated for 2 years with tamoxifen, although
this was not statistically significant (hazard ratio (HR) = 2.84,
95% confidence interval (CI) = 0.68 to 11.99, P = 0.15). In the
group randomised to 5 years' tamoxifen the survival pattern
shifted towards a significantly improved recurrence-free survival
(RFS) among CYP3A5*3-homozygous patients (HR = 0.20,
95% CI = 0.07 to 0.55, P = 0.002). No reliable differences
could be seen between treatment duration and the genotypes of
CYP2D6, SULT1A1 or UGT2B15. The significantly improved
RFS with prolonged tamoxifen treatment in CYP3A5*3
homozygotes was also seen in a multivariate Cox model (HR =
0.13, CI = 0.02 to 0.86, P = 0.03), whereas no differences
could be seen for CYP2D6, SULT1A1 and UGT2B15.
Conclusion The metabolism of tamoxifen is complex and the
mechanisms responsible for the resistance are unlikely to be
explained by a single polymorphism; instead it is a combination
of several mechanisms. However, the present data suggest that
genetic variation in CYP3A5 may predict response to tamoxifen
therapy.
Introduction
Tamoxifen is widely used as an endocrine treatment for
patients with oestrogen-receptor (ER)-positive breast cancer.
Five years of adjuvant tamoxifen therapy reduces the risk of
recurrence and prolongs the survival of women with ER-posi-
tive tumours [1]. Nevertheless, in a proportion of patients,
tumours are resistant to tamoxifen, or become so, with a sub-
sequent relapse in the disease. The mechanisms underlying
CI = confidence interval; CYP3A4 = cytochrome P450 3A4; CYP3A5 = cytochrome P450 3A5; CYP2D6 = cytochrome P450 2D6; ER = oestrogen 
receptor; HR = hazard ratio; PCR = polymerase chain reaction; RFS = recurrence-free survival; SSRI = selective serotonin reuptake inhibitors; 
SULT1A1 = sulphotransferase 1A1; TEAA = triethylammonium acetate; UGT2B15 = UDP-glucuronosyltransferase 2B15.Breast Cancer Research    Vol 9 No 1    Wegman et al.
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the resistance are not fully understood. Because there is con-
vincing evidence that tamoxifen is converted to anti-oestro-
genic metabolites that are more potent than the mother
substance, one hypothesis is that altered metabolism might
contribute to inter-individual variability in serum concentra-
tions, which in turn may influence the action on ER and the
response to treatment [2-4]. Some studies have demonstrated
considerable inter-individual variation in concentrations of
tamoxifen metabolites both in plasma and locally in the breast
[5,6].
Several primary metabolites have been identified, including N-
desmethyl-tamoxifen, 4-hydroxy-N-desmethyl-tamoxifen
(endoxifen) and 4-hydroxy-tamoxifen. Whereas tamoxifen has
a relatively low affinity for ER, the metabolite 4-hydroxy-
tamoxifen binds with an affinity similar to that of oestradiol
[7,8]. It has also been demonstrated by studies in vitro that
endoxifen exhibits a cpotency similar to that of 4-hydroxy-
tamoxifen with regard to ER binding affinity, suppression of
oestrogen-dependent cell growth and gene expression [2-4].
N-desmethyl-tamoxifen, in contrast, is a weak anti-oestrogen
[2,3,7-9]. Previous studies have shown that cytochrome P450
3A4 and cytochrome P450 3A5 (CYP3A4 and CYP3A5) are
the major catalysts of N-demethylation, whereas the 4-hydrox-
ylation is predominantly supported by the cytochrome P450
2D6 (CYP2D6) [10-12]. The 4-hydroxy-tamoxifen is in equilib-
rium between a trans and a cis isoform, resulting in a proposed
shift in property from a potent anti-oestrogen towards a signif-
icantly less potent one [13-15]. Cis-4-hydroxy-tamoxifen has in
addition been reported to exist at higher concentrations than
trans-4-hydroxy-tamoxifen in patients with breast cancer with
acquired resistance to tamoxifen [16]. Nishiyama and col-
leagues [17] suggested a geometrical selectivity in both the
sulphation of trans-4-hydroxy-tamoxifen and the glucuronida-
tion of cis-4-hydroxy-tamoxifen, and that these reactions were
catalysed by sulphotransferase 1A1 (SULT1A1) and UDP-glu-
curonosyltransferase 2B15 (UGT2B15), respectively [17].
Polymorphisms affecting enzyme activity have been found in
CYP3A5, CYP2D6, SULT1A1 and UGT2B15. The most fre-
quent and functionally important polymorphism in the CYP3A5
gene consists of an A6986G transition within intron 3
(CYP3A5*3). This polymorphism creates an alternative splice
site resulting in a frame shift and truncation of the protein [18-
20]. In CYP2D6  the most common non-functional allele is
CYP2D6*4. This polymorphism generates a G→A transition
at the first nucleotide of exon 4 in the CYP2D6 gene, leading
to a truncated non-functional gene product [21]. Further, the
most frequent polymorphism in the SULT1A1 gene is a G→A
transition at nucleotide 638, defining the SULT1A1*2 allele,
which is correlated with a diminished capacity to sulphate
SULT1A1 substrates [22]. Several polymorphisms have also
been found within the UGT2B15 gene although only two in
the coding region [23]. One causes an amino acid shift from
aspartate (UGT2B15*1) to tyrosine (UGT2B15*2) at position
85 of the UGT2B15 protein, a shift that has been associated
with an increase in enzyme activity [24]. In a previous study we
investigated functional polymorphisms in CYP2D6  and
SULT1A1 in 226 postmenopausal patients with breast cancer
randomised to treatment with or without tamoxifen. We found
a benefit of tamoxifen in carriers of the inactive allele
CYP2D6*4  and a tendency in patients homozygous for
SULT1A1*1, when compared with the control population [25].
In the present study a new cohort was investigated that was
both larger and included additional polymorphic enzymes
involved in the metabolism of tamoxifen. The polymorphisms of
CYP3A5 (CYP3A5*1 and *3), CYP2D6 (CYP2D6*1 and *4),
SULT1A1 (SULT1A1*1 and *2) and UGT2B15 (UGT2B15*1
and *2) were examined in tamoxifen-treated postmenopausal
patients with breast cancer, to discern whether the genotypes
correlated with clinical/pathological factors and/or to the ben-
efit of tamoxifen. We proposed that the alleles contributing to
the bioactivation of tamoxifen (namely CYP3A5*1  and
CYP2D6*1) as well as the alleles delaying the elimination of




We analysed frozen tumour tissues from 677 postmenopausal
patients with stage II and III breast cancer. They were diag-
nosed between 1986 and 1997 in the South East Health Care
Region of Sweden and were between 50 and 96 years old,
with a mean age of 69 years at the time of diagnosis. Informa-
tion on tumour size, lymph-node status and tumour stage is
shown in Table 1. All patients were ER-positive and had
received adjuvant postoperative tamoxifen therapy. A sub-
group of 238 patients was randomised to either 2 or 5 years
of treatment with tamoxifen. Patients diagnosed before 1994
received a daily dosage of 40 mg tamoxifen for 2 or 5 years.
After 1 January 1994 all postmenopausal patients received 20
mg for 5 years. In the non-randomised group (n = 439) 175
patients were treated with 40 mg and 264 patients with 20 mg
of tamoxifen. The mean follow-up time in the total population
was 7.3 years (range 0.04 to 17.9, median 7.08). For the ran-
domised group the mean follow-up time in the 2-year arm was
9.8 years (range 2.3 to 17.7, median 9.8) and in the 5-year arm
10.7 years (range 2.1 to 17.9, median 10.7). The study was
approved by the local ethical committee in Linköping, Sweden
(register number 03-608).
DNA isolation and PCR
Fresh frozen breast tumour tissues (about 30 mg) were
homogenised with a microdismembrator (B Braun, Melsun-
gen, Germany), and genomic DNA was then isolated with the
SV Genomic DNA Purification System (Promega Corporation,
Madison, WI, USA). The DNA content was determined by
spectrophotometry, and purified DNA was stored at -20°C
before use.Available online http://breast-cancer-research.com/content/9/1/R7
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The  CYP3A5,  CYP2D6,  SULT1A1  and  UGT2B15  genes
were amplified by PCR in separate reactions with 50 ng of
DNA. The primer sequences used in the PCR of CYP2D6 and
SULT1A1 were adopted from Hanioka and colleagues [21]
and Coughtrie and colleagues [26], respectively, whereas the
CYP3A5 and UGT2B15 genes were amplified with forward
(5'-ACCACCCAGCTTAACGAATG-3' and 5'-AGAGCTTGT-
TCAGAGGGGTCATGAG-3') and reverse (5'-AGCACAG-
GGAGTTGACCTTC-3' and 5'-
AAATTCTCGATAGATGGATATATGG-3') primers, respec-
tively. The following PCR reagents were added to a reaction
volume of 20 μl: 2 mM MgCl2, 0.2 mM dNTPs, 0.5 unit of Taq
DNA polymerase, and 1 μM each of forward and reverse
primer in 1 × PCR buffer. The amplification was performed in
a PTC-200 Peltier Thermal Cycler DNA Engine (MJ
Research™ Inc, Waltham, MA, USA). An initial denaturation at
94°C for 3 minutes was followed by 38 to 40 cycles of 30 sec-
onds at 94°C, 30 seconds of annealing at 63°C (CYP2D6,
SULT1A1) or 64°C (CYP3A5, UGT2B15), and 40 seconds of
extension at 72°C. An extension period of 5 minutes followed
the final cycle. Fragments were then resolved by electrophore-
sis on a 2% (w/v) agarose gel containing 1 × TBE (89 mM Tris,
89 mM boric acid, 2 mM EDTA, pH 8.4) buffer and ethidium
bromide (0.5 μg/μl). The gel was finally processed in an ultra-
violet detector (Spectromics Corporation, New York, NY,
USA).
Restriction fragment length polymorphism
The CYP2D6 and SULT1A1 polymorphisms were detected
by using restriction enzymes. The MvaI restriction enzyme dis-
tinguishes between the CYP2D6*4 and other CYP2D6 alle-
les. The polymorphic allele CYP2D6*4 lacks the restriction
site and is thereby retained as one fragment. The wild-type
allele SULT1A1*1 has a restriction site recognised by HaeII
but the polymorphic allele SULT1A1*2 does not. MvaI (10
units; Fermentas, Stockholm, Sweden) and 1.5 μl of R+ buffer
(supplied by the manufacturer) were added to each tube of
CYP2D6 PCR products and incubated at 37°C for 2.5 hours.
Table 1
Use of χ2 test to compare genotype and tumour characteristics in ER-positive patients with breast cancer
Genotype Characteristics
Tumour size (mm)a Tumour stage Nodal involvement
≤20 21–50 >50 II III 0 1–3 >4
CYP3A5 (n = 663) n (%) n (%) n (%)
*1/*1 1 (14.3) 5 (71.4) 1 (14.3) 6 (85.7) 1 (14.3) 3 (42.9) 3 (42.9) 1 (14.3)
*1/*3 28 (30.4) 59 (64.1) 5 (5.4) 83 (89.2) 10 (10.8) 27 (29.0) 45 (48.4) 21 (22.6)
*3/*3 150 (26.8) 369 (66.0) 40 (7.2) 479 (85.1) 84 (14.9) 177 (31.4) 220 (39.1) 166 (29.5)
P 0.78 0.57 0.40
CYP2D6 (n = 677)
*1/*1 132 (28.9) 294 (64.3) 31 (6.8) 393 (85.4) 67 (14.6) 142 (30.9) 194 (42.2) 124 (27.0)
*1/*4 45 (24.7) 125 (66.7) 12 (6.6) 159 (86.9) 24 (13.1) 56 (30.6) 73 (39.9) 54 (29.5)
*4/*4 9 (27.3) 21 (63.6) 3 (9.1) 29 (85.3) 5 (14.7) 10 (29.4) 14 (41.2) 10 (29.4)
P 0.83 0.89 0.98
SULT1A1 (n = 677)
*1/*1 77 (30.5) 163 (64.7) 12 (4.8) 223 (88.1) 30 (11.9) 80 (31.6) 104 (41.1) 69 (27.3)
*1/*2 79 (25.0) 209 (66.1) 28 (8.9) 269 (84.3) 50 (15.7) 85 (26.6) 142 (44.5) 92 (28.8)
*2/*2 30 (28.8) 68 (65.4) 6 (5.8) 89 (84.8) 16 (15.2) 43 (41.0) 35 (33.3) 27 (25.7)
P 0.26 0.41 0.09
UGT2B15 (n = 445)
*1/*1 38 (31.6) 71 (59.2) 11 (9.2) 99 (82.5) 21 (17.5) 41 (34.2) 41 (34.2) 38 (31.6)
*1/*2 46 (24.9) 129 (69.7) 10 (5.4) 160 (85.6) 27 (14.4) 58 (31.0) 75 (40.1) 54 (28.9)
*2/*2 40 (29.2) 82 (59.9) 15 (10.9) 110 (79.7) 28 (20.3) 37 (26.8) 68 (49.3) 33 (23.9)
P 0.18 0.38 0.18
Results are shown as n (%). ER, oestrogen receptor. aInformation on tumour size was missing for five patients.Breast Cancer Research    Vol 9 No 1    Wegman et al.
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The SULT1A1 PCR products were incubated with 5 units of
the restriction enzyme HaeII (New England BioLabs, Beverly,
MA, USA) in a 20 μl reaction mixture containing 1 × NE buffer
(50 mM potassium acetate, 20 mM Tris-acetate, 10 mM mag-
nesium acetate, 1 mM dithiothreitol, pH 7.9; New England
BioLabs) supplemented with 100 μg/ml bovine serum albu-
min. After digestion, fragments were resolved by electrophore-
sis on a 3% (w/v) agarose gel containing 1 × TBE buffer and
ethidium bromide (0.5 μg/μl). The gel was finally processed in
an ultraviolet detector. To confirm the genotypes obtained with
the restriction fragment length polymorphism method, 20 ran-
domly selected samples were DNA sequenced and no differ-
ences in genotype were detected between the methods.
Transgenomic Wave® – nucleic acid fragment analysis 
system (denaturing high-performance liquid 
chromatography)
The Transgenomic Wave® system is based on the principle of
liquid chromatography and was used to separate and detect
the CYP3A5*1, *3 and UGT2B15*1, *2 alleles amplified by
PCR. In this system, DNA fragments are carried by a gradient
buffer (with a 2% increase in buffer per minute) through a
DNASep®  Cartridge under isothermal (58°C and 55.6°C,
respectively) conditions, with subsequent detection by
absorbance at 260 nm. The buffers used in the system con-
sists of 0.1 M triethylammonium acetate (TEAA) and 25% (v/
v) acetonitrile and 0.1 M TEAA (gradient buffer). To estimate
the retention pattern for the UGT2B15 and CYP3A5 alleles, a
few samples were DNA sequenced by a Thermo Sequenase
Kit (Amersham Pharmacia Biotech, Uppsala, Sweden) and
used as controls for each genotype.
Statistical analyses
SPSS Advanced Models™ 12.0 software was used for the sta-
tistical analyses. The χ2 test was used to show differences in
the distribution of genotypes according to lymph-node status,
tumour size and tumour stage. In the survival analyses, each
woman's contribution to the person-years at risk began from
the date of initial surgery to 1 January 2004, to the date of local
or distant recurrences, whichever was earlier. The survival
curves of recurrences were estimated with the Kaplan–Meier
method, and the significance of differences between survival
rates, for patients with different genotypes and endocrine
treatment, was assessed by log-rank test. A univariate Cox
proportional-hazard model was used for the estimation of the
hazard ratio (HR) comparing genotype for each treatment
group. Further, we performed a multivariate Cox model to
adjust for the different tumour characteristics between the
genotypes. We also tested whether the calculated hazard
ratios were significantly different between treatment groups by
using an interaction test according to the Cox model (treat-
ment (0/1), genotype (0/1) and treatment × genotype (0/1)).
Differences between groups were judged significant at confi-
dence levels greater than 95% (P < 0.05).
Results
The frequencies of the most common alleles were 0.92
(CYP3A5*3), 0.82 (CYP2D6*1), 0.61 (SULT1A1*1) and 0.52
(UGT2B15*2). Homozygous genotypes representing blocked
or diminished enzymatic activity, CYP3A5*3, CYP2D6*4 and
SULT1A1*2, were seen in 84.9%, 5.0% and 15.2% of the
patients, respectively. Information on genotype and tumour
characteristics is shown in Table 1. There was no significant
difference in the distribution of tumour characteristics accord-
ing to genotype.
To evaluate whether the genotypes were of prognostic impor-
tance in terms of recurrence-free survival (RFS), we calculated
each polymorphism separately. The Kaplan–Meier estimates
demonstrated that patients homozygous for the CYP2D6*4
allele had a significantly better prognosis than patients who
were homozygous or heterozygous for the *1 allele (P = 0.05
and P = 0.04, respectively) (Figure 1). In a multivariate Cox
analysis including tumour stage, tumour size and lymph-node
status, the result for CYP2D6 was less clear (P = 0.055). For
CYP3A5, SULT1A1 and UGT2B15, no significant difference
was seen regarding prognosis (data not shown).
Among the 677 postmenopausal patients with breast cancer,
a subgroup (n = 238) was randomised to either 2 or 5 years
of adjuvant tamoxifen. In the randomised group we examined
whether the genotypes of CYP3A5, CYP2D6, SULT1A1 and
UGT2B15 could influence the benefit of tamoxifen. When cal-
culating the predictive value, cases with less than 2 years of
follow-up time were excluded. In the statistical analyses we
combined homozygous and heterozygous patients to equalise
the different groups when the number of either homozygous
genotype was low. Initially, we compared the RFS by genotype
and by randomisation with log-rank test. Next, we estimated
the HR for each genotype in the two treatment groups by
using a univariate Cox proportional hazard model. Finally, we
performed a multivariate Cox model adjusted for tumour char-
acteristics such as stage, size, lymph-node involvement and
tamoxifen duration. The predictive value of each genotype was
further evaluated with an interaction test that compared the
estimated HRs.
The HRs presented in Table 2 demonstrate significant associ-
ations for the SULT1A1 and CYP3A5 genotypes and RFS.
We found an improved RFS with 2 years of tamoxifen in
homozygous carriers of the SULT1A1*1 allele (HR = 0.33,
95% CI = 0.12 to 0.96, P = 0.04). However, no such differ-
ence was detected in patients randomised to 5 years of
tamoxifen. The survival curves of SULT1A1 are shown in Fig-
ure 2.
For CYP3A5, homozygous carriers of the *3 allele tended to
have an increased risk of recurrence when treated with 2 years
of tamoxifen, although this was not statistically significant (HR
= 2.84, 95% CI = 0.68 to 11.99, P = 0.15; Table 2 and FigureAvailable online http://breast-cancer-research.com/content/9/1/R7
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3a). In the group randomised to 5 years of tamoxifen the sur-
vival pattern shifted towards a significantly improved RFS
among CYP3A5*3 homozygous patients (HR = 0.20, 95% CI
= 0.07 to 0.55, P = 0.002; Table 2). The survival curve is
shown in Figure 3b (P = 0.0005). When comparing HRs the
benefit of 5 years of tamoxifen associated with homozygous
carriers of the CYP3A5*3 allele persisted (P = 0.003; Table
2). The other genes examined (CYP2D6  and  UGT2B15)
showed no significant difference by genotype (Figures 4 and
5 and Table 2), even though patients homozygous or hetero-
zygous for CYP2D6*4 had a tendency towards improved ben-
efit of 5 years of tamoxifen compared with patients
homozygous for CYP2D6*1 (P = 0.12). Furthermore, when
we adjusted for tamoxifen duration, tumour stage, tumour size
and lymph-node status and performed an interaction test
when significance occurred, patients homozygous for
CYP3A5*3 still had a significantly decreased risk of recur-
rence when treated for 5 years with tamoxifen (HR = 0.13, CI
= 0.02 to 0.86, P = 0.03). No differences could be seen for
CYP2D6, SULT1A1 and UGT2B15.
Discussion
In a previous report of patients with breast cancer randomised
to treatment with and without tamoxifen we found that genetic
polymorphism in CYP2D6 and SULT1A1 may predict the ben-
efit of tamoxifen therapy with a significantly improved disease-
free survival in patients that were carriers of the CYP2D6*4
allele and/or were homozygous for the SULT1A1*1 allele [25].
In the present investigation we examined a different and larger
cohort, which also included additional polymorphic enzymes
that participate in the biotransformation and elimination of
tamoxifen. The study design between these investigations dif-
fers, because all patients received tamoxifen in the current
study. However, of the 677 patients with breast cancer ana-
lysed, a subgroup was randomised to either 2 or 5 years of
tamoxifen and an attempt was made to calculate the predictive
value of the polymorphic enzymes within the randomised pop-
ulation (n = 238). In this population, patients were treated dif-
Figure 1
Kaplan–Meier estimates for recurrence-free survival between CYP2D6  genotypes in oestrogen-receptor-positive postmenopausal breast can- cer patients Kaplan–Meier estimates for recurrence-free survival between CYP2D6 
genotypes in oestrogen-receptor-positive postmenopausal breast can-
cer patients. The black solid line represents patients homozygous for 
CYP2D6*1, the grey solid line represents heterozygous patients, and 
the dotted line represents patients homozygous for CYP2D6*4. P = 
0.05 between *4/*4 and *1/*1; P = 0.04 between *4/*4 and *1/*4; P = 
0.16 between *1/*1 and *1/*4.
Table 2
Hazard ratio (HR) between genotypes and randomisation calculated with the Cox proportional-hazard model
Genotype Duration of tamoxifen treatment
2 years 5 years
HR (n) 95% CI P HR (n)9 5 %  C I P
CYP3A5*1/*1, *1/*3 1.00 (16) 1.00 (13)
CYP3A5*3/*3 2.84 (83) 0.68–11.99 0.15 0.20 (95) 0.07–0.55 0.002
CYP2D6*1/*1 1.00 (72) 1.00 (79)
CYP2D6*1/*4, *4/*4 0.87 (31) 0.38–1.97 0.74 0.33 (32) 0.08–1.43 0.14
SULT1A1*1/*2, *2/*2 1.00 (71) 1.00 (73)
SULT1A1*1/*1 0.33 (32) 0.12–0.96 0.04 0.83 (36) 0.29–2.36 0.73
UGT2B15*1/*1 1.00 (17) 1.00 (26)
UGT2B15*1/*2, *2/*2 1.18 (62) 0.39–3.52 0.77 1.94 (55) 0.53–7.06 0.31
Cases with less than 2 years of follow-up time were excluded. For each randomisation, patients with the proposed 'low-risk' alleles were used as 
reference. CI, confidence interval.Breast Cancer Research    Vol 9 No 1    Wegman et al.
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ferently 2 years after the start of tamoxifen treatment and we
therefore compared RFS for each randomised group and gen-
otype. In the group treated with 5 years of tamoxifen we found
that patients homozygous for the CYP3A5*3 variant allele had
a significantly improved RFS compared with patients harbour-
ing the CYP3A5*1 allele, and we could also see a weak ten-
dency for a decreased risk of recurrence in patients who were
carriers of the CYP2D6*4 variant allele. However, the rele-
vance of this finding is uncertain because the number of
patients was limited.
A comparison of the hazard ratios calculated for each treat-
ment group demonstrated that the risk reduction was signifi-
cantly higher in patients homozygous for the CYP3A5*3 allele
than in those harbouring the CYP3A5*1 allele. This was also
true when we adjusted for tumour size, tumour stage and
lymph-node status. No association between the outcome of
tamoxifen treatment and the genotypes of CYP2D6,
SULT1A1 and UGT2B15 was found. Even if the assessment
of CYP2D6 showed no significant influence in the randomised
groups, there was a tendency for an advantage with 5 years of
Figure 2
Recurrence-free survival in ER-positive patients with different geno- types of SULT1A1 and tamoxifen randomisation Recurrence-free survival in ER-positive patients with different geno-
types of SULT1A1 and tamoxifen randomisation. The solid line repre-
sents patients homozygous for the SULT1A1*1 allele, and the dotted 
line represents patients homozygous or heterozygous for the 
SULT1A1*2 allele. (a) SULT1A1 and 2 years of tamoxifen therapy; (b) 
SULT1A1 and 5 years of tamoxifen therapy.
Figure 3
Recurrence-free survival in ER-positive patients with different geno- types of CYP3A5 and tamoxifen randomisation Recurrence-free survival in ER-positive patients with different geno-
types of CYP3A5 and tamoxifen randomisation. The solid line repre-
sents patients homozygous or heterozygous for the CYP3A5*1 allele, 
and the dotted line represents patients homozygous for the CYP3A5*3 
allele. (a) CYP3A5 and 2 years of tamoxifen therapy; (b) CYP3A5 and 
5 years of tamoxifen therapy.Available online http://breast-cancer-research.com/content/9/1/R7
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tamoxifen in carriers of at least one CYP2D6*4 allele. This is
partly in agreement with our previous findings [25] and with
those of Nowell and colleagues [27], who noted that the
CYP2D6*4 variant seemed to be associated with a decreased
risk of death or recurrence. In contrast, a recent prognostic
study by Goetz and colleagues [28] demonstrated that
patients homozygous for CYP2D6*4  had both significantly
worse relapse-free time and disease-free survival but not over-
all survival. Because their homozygous CYP2D6*4 genotype
constitutes a small number of patients, results should there-
fore be confirmed in a larger patient population.
Several studies have been performed on the CYP3A5 enzyme
and tamoxifen, although results are controversial. The reports
have focused mainly on the concentration of metabolites and
its association with genotype or patient outcome. Goetz and
colleagues [28] attempted to investigate whether CYP3A5*3
polymorphism affected patient outcome. They found no differ-
ences in relapse-free time, disease-free survival or overall
survival by CYP3A5*3  genotype. Our novel findings of an
improved RFS in patients homozygous for CYP3A5*3 was
Figure 4
Recurrence-free survival in ER-positive patients with different geno- types of CYP2D6 and tamoxifen randomisation Recurrence-free survival in ER-positive patients with different geno-
types of CYP2D6 and tamoxifen randomisation. The solid line repre-
sents patients homozygous for the CYP2D6*1 allele, and the dotted 
line represents patients homozygous or heterozygous for the 
CYP2D6*4 allele. (a) CYP2D6 and 2 years of tamoxifen therapy; (b) 
CYP2D6 and 5 years of tamoxifen therapy.
Figure 5
Recurrence-free survival in ER-positive patients with different geno- types of UGT2B15 and tamoxifen randomisation Recurrence-free survival in ER-positive patients with different geno-
types of UGT2B15 and tamoxifen randomisation. The solid line repre-
sents patients homozygous for the UGT2B15*1 allele, and the dotted 
line represents patients homozygous or heterozygous for the 
UGT2B15*2 allele. (a) UGT2B15 and 2 years of tamoxifen therapy; (b) 
UGT2B15 and 5 years of tamoxifen therapy.Breast Cancer Research    Vol 9 No 1    Wegman et al.
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unexpected because this genotype represents an inactive
form of the enzyme and should therefore not catalyse the
formation of the primary metabolite N-desmethyl-tamoxifen,
which is a precursor of the ER-active metabolite endoxifen.
Tucker and colleagues [29] recently tested whether genetic
polymorphisms in CYP3A5  were associated with altered
metabolism of tamoxifen in patients with breast cancer. They
found no significant differences in tamoxifen or metabolite
concentration by CYP3A5*3 polymorphic status. In contrast,
Jin and colleagues [30] suggested that subjects who carried
at least one CYP3A5*1 allele had higher plasma concentra-
tions of endoxifen than those lacking functional CYP3A5 alle-
les (namely *3/*3), although this was not statistically
significant. In addition, several authors have proposed that
CYP3A5 might be a minor contributor to the overall metabo-
lism of CYP3A substrates [31-33]. There is also a large over-
lap in substrate specificity between CYP3A4 and CYP3A5, so
the contribution of each CYP3A4 and CYP3A5 to total
CYP3A activity could thus depend on both the drug and the
individual exposed to it [34].
The influence of SULT1A1 in the current investigation did not
reveal any conclusive implication, either in the prognostic nor
in the predictive evaluation. The SULT1A1*1 allele was previ-
ously investigated by Nowell and colleagues [35] and by our
group [25]; both studies indicated that the high-activity allele
SULT1A1*1 contributed significantly to tamoxifen response.
In a more recent study by Nowell and colleagues [27], genetic
polymorphism in SULT1A1 and UGT2B15 was analysed in
patients with breast cancer treated with or without tamoxifen.
They demonstrated that genetic variation in these phase II
enzymes alone or in combination was associated with overall
survival and recurrence of disease. Individuals possessing
both UGT2B15*2 and SULT1A1*2 alleles had a significantly
increased risk of death. SULT1A1 was also investigated by Jin
and colleagues [30], who studied whether the mean plasma
concentration of tamoxifen and its metabolites was associated
with genetic variants of this gene, but no such correlation was
found.
Co-administration of drugs (such as selective serotonin
reuptake inhibitors (SSRI)) used in patients with breast cancer
has been shown to inhibit the metabolism of tamoxifen [2,30].
This is an important issue because changes in the concentra-
tions of active metabolites might influence the outcome of
therapy; however, results are controversial [2,30,36,37]. The
influence from SSRI co-administration in our investigation is
likely to be a minor problem because such drugs were rarely
used in the current study population.
In the present study, only tumour DNA was available for geno-
typing and this introduces a risk for misclassification of geno-
types because loss of heterozygosity and gene mutations
frequently occur at several sites during carcinogenesis.
However, breast tumour tissues are a mixture of stromal,
inflammatory and malignant cells, and genetic lesions usually
affect only a subgroup of tumour cells. Therefore the presence
of normal cells and malignant cells without DNA lesions in the
locus of CYP3A5,  CYP2D6,  SULT1A1  and  UGT2B15
decreases the risk of genotype misclassification. This is also
supported by the fact that allele frequencies of CYP3A5*3,
CYP2D6*1,  SULT1A1*2  and  UGT2B15*2  in the current
study population are comparable to those reported by others
in Caucasian populations [18,19,26,27].
Conclusion
Taken together, the current investigation and earlier published
reports [25,27,35] of randomised patients connected with
polymorphisms in metabolic enzymes and the outcome of
tamoxifen give rise to questions about the hypothesis that
genotypes contributing to the biosynthesis of the ER-active
metabolites (such as endoxifen and 4-hydroxy-tamoxifen)
improve the benefit of tamoxifen. Investigations by Nowell's
group [35] and from our laboratory indicate that patients who
carry the SULT1A1*1,  CYP2D6*4  and  CYP3A5*3  alleles,
which give less ER-active metabolites, might benefit from
tamoxifen [25,27], whereas others have found the opposite,
particularly regarding CYP2D6 [28]. However, the metabolism
of tamoxifen is complex and the enzymes contributing in this
process can also be affected by co-prescribed drugs. The
mechanisms responsible for the resistance are therefore
unlikely to be explained by a single polymorphism but rather by
a combination of several mechanisms. Nevertheless, the
present investigation suggests that the genotype of CYP3A5
may contribute to tamoxifen response.
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